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ABSTRACT 
Objective: The present study was aimed to investigate the safety, reliability of Gliclazide and possible drug interaction with Itopride when they 
were administered as combination treatment.  
Methods: Studies were conducted in normal and streptozotocin induced diabetic rats with oral administration of selected doses of gliclazide, 
itopride and their combination. Blood samples were collected from rats by retro orbital/marginal ear vein puncture at regular intervals of time. All 
the blood samples were analyzed for pharmacokinetic parameters by HPLC method.  
Results: There was no significant difference in pharmacokinetic parameters of both Gliclazide alone and combination with itopride in healthy and 
diabetic rats on day 1 and day 8.  
Conclusion: Based on the results it can be concluded that the concurrent administration of these two drugs have potential benefit without any drug 
interactions in the effective management of diabetes and gastroparesis. 
Keywords: Drug interactions, Gliclazide, Itopride, Pharmacokinetics, Gastroparesis, Diabetes mellitus. 
 
INTRODUCTION 
Diabetes mellitus is a metabolic disease in which there are 
high blood sugar levels over a prolonged period. Diabetes mellitus is 
due to the pancreas not producing enough insulin or the cells 
Normally, the muscles of the stomach, which are controlled by the 
vagus nerve, contract to break up food and move it through the 
gastrointestinal (GI) tract.
of the 
body not responding properly to the insulin produced [1]. 
 
Gastroparesis is a syndrome characterized by delayed gastric 
emptying [2], in the absence of mechanical obstruction of the 
stomach. The cardinal symptoms include postprandial fullness 
(early satiety), nausea, vomiting and bloating [3]. In one tertiary 
referral series, diabetes accounted for almost one third of cases of 
Gastroparesis [4]. Diabetes patients with gastroparesis develop 
retinopathy, neuropathy, nephropathy, nutritional compromise, 
impaired glucose control, and a poor quality of life [5].  
Diabetes is the most common known 
cause of gastroparesis. People with diabetes have high levels of 
blood glucose, also called blood sugar. Over time, high blood glucose 
levels can damage the vagus nerve. 
Symptoms attributable to gastroparesis are reported by 5 to 12% of 
patients with diabetes [6, 7, 8, and 9]. Gliclazide is an oral hypoglycemic 
(anti-diabetic drug) and is classified as a sulfonylurea. Its classification 
has been ambiguous, as literature uses it as both a first-generation [10], 
and second-generation [11] sulfonylurea. Gliclazide was shown to 
protect human pancreatic beta-cells from hyperglycemia-
induced apoptosis [12]. It was also shown to have an antiatherogenic 
effect (preventing accumulation of fat in arteries) in type 2 diabetes [13]. 
Itopride is a prokinetic benzamide derivative unlike metoclopramide 
 or domperidone. These drugs inhibit dopamine and have a gastro 
kinetic effect [14]. Itopride is indicated for the treatment of 
functional dyspepsia and other gastrointestinal conditions [15]. After 
oral administration Itopride undergoes rapid and extensive absorption 
with levels of itopride peaking in the blood plasma after only 35 min. 
Itopride is primarily eliminated via the kidneys having an elimination 
half-life 
To treat the coexisting disease, multidrug therapy is inevitable and 
there is every possibility for a drug interaction to occur when drugs 
are concomitantly used [17]. 
of approximately 6 h [16]. 
MATERIALS AND METHODS 
Materials 
Drugs and chemicals 
Gliclazide and Itopride 
Methods 
were procured from Matrix laboratories as a 
gift sample. Streptozotocin (STZ) was purchased from Sigma Chemical 
Co. The glucose estimation (GOD-POD) kit (Excel diagnostic, 
Hyderabad) was procured from the drug store. All HPLC grade 
solvents (methanol and water) were procured from Finar chemicals 
Ltd., Ahmadabad. All chemicals used were analytical grade. 
Animal study  
Twenty four healthy Wistar rats were (Weighing 200-220 g) 
selected for this study, all the animals were healthy during the 
period of the experiment. All efforts were made to maintain the 
animals under controlled environmental conditions (Temperature 
25 °C, Relative Humidity 45% and 12 h alternate lights and dark 
cycle) with 100 % fresh air exchange in animal rooms, 
uninterrupted power and water supply. Rats were fed with standard 
diet and water ad libitum. 
Induction of experimental diabetes 
The protocol of animal study was 
approved by the institutional animal ethics committee (IAEC NO: 
P16/VCP/IAEC/2012/3/VVR/AE2). 
Male Wistar rats (200-250 gms) were fasted for 16 h before the 
induction of diabetes with Streptozotocin (STZ), Animals (n=6) were 
injected intra peritoneal with 0.22-0.25 ml of freshly prepared 
solution of STZ (60 mg/ml in 0.01 m citrate buffer, pH 4.5) at a final 
dose of 60 mg/kg body wt. The diabetic state was assessed in STZ-
treated rats by measuring the non-fasting serum glucose 
concentration after 48 h. Only rats with serum glucose levels greater 
than 300 mg/dl were selected and used in this experiment. 
Study design [18] 
The rats were grouped as follows 
Group I: Gliclazide (30 mg/kg, oral) alone in single dose/day in 
diabetic rats up to 8 d.  
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Group II: Itopride (20 mg/kg, oral) alone in single dose/day in 
diabetic rats up to 8 d.  
Group III: Itopride (20 mg/kg, oral) alone in single dose/day in 
normal healthy rats up to 8 d 
Group IV: Gliclazide (30 mg/kg, oral) and Itopride concomitant 
administration in diabetic rats as Single dose/day up to 8 d. 
Collection of blood samples  
Blood samples were collected after administration of Gliclazide 30 
mg/kg, Itopride 20 mg/kg as per animal body weight on day 1 and 
day 8 blood samples of 1 ml were drawn from each anesthetized 
(isoflurane) rat at pre-determined time intervals was collected from 
the retro-orbital plexus using a capillary tube into pre-labeled 
eppendorf tubes containing 10% of K2
For HPLC analysis C18 column with 5μm particle size, mobile Phase 
consisting of 0.05M Potassium Dihydrogen phosphate and 0.5% Tri 
Ethyl Amine (TEA) buffer having pH 2.7, and Methanol in the ratio of 
60:40 v/v. The flow rate was 0.8 ml/min and the effluents were 
monitored at 238 nm. Internal standard Phenformin was used. The 
retention time of an internal standard (phenformin), gliclazide and 
itopride in plasma were 9.8, 7.2 and 3.3 min, respectively [21]. 
EDTA anticoagulant (20 μl). 
The time intervals for the sample collection were 0 (Pre dose), 0.5, 1, 
2, 4, 6, 8 and 24 h (post dose), Equal amount of saline by oral route 
was administered to replace blood volume at every blood 
withdrawal time.  
Plasma was obtained by centrifuging blood samples by using 
refrigerated (REMI ULTRA) at 3000 rpm for 5 min. The obtained 
plasma samples were transferred into pre-labeled micro centrifuge 
tubes and stored at −2 0 °C until analysis of pharmacokinetic 
parameters. As described above, all the procedures were followed 
on day 8 also. Pharmacokinetic parameters were calculated by non-
compartmental analysis by using Win Nonlin5.1 software [19, 20]. 
Method of analysis  
Preparation of plasma samples for HPLC analysis  
Rat plasma (0.5 ml) samples were prepared for chromatography by 
precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was suspended with 1 
ml of acetonitrile by vortexing for 1 min. After centrifugation (5000–
6000 rpm for 10 min), acetonitrile was added to the ethanol and the 
organic mixture was taken to near dryness by a steam of nitrogen at 
room temperature. Samples were reconstituted in 200 µ1 of mobile 
phase were injected for HPLC analysis. 
Standard calibration curve of Gliclazideand Itopride in rat plasma  
Different concentrations (0.05, 0.1, 0.5, 1, 5, 10, 20, 40 µg/ml) of 
gliclazide, itopride in plasma were prepared for calibration curve. 
The samples were treated as above for protein precipitation method 
and peak areas of gliclazide and Itopride were noted down. The peak 
area ratios obtained at different concentrations of the gliclazide and 
Itopride were plotted using UV–Vis detector at 238 nm.  
Pharmacokinetic analysis  
Plasma concentration versus time data was analyzed using standard 
non-compartment analysis. AUC0-t refers to the AUC from 0 to 24 h, 
which was determined by linear trapezoidal rule and AUC0-α refers to 
the AUC from time at zero hours to infinity. The AUC0-α was calculated 
using the formula AUC0-t+[Clast/K] where C last 
Statistical analysis  
is the concentration in 
µg/ml at the last time point and K is the elimination rate constant. 
Various pharmacokinetic parameters like area under the curve [AUC], 
elimination half life [t½]. Apparent volume of distribution (V/f) total 
clearance (Cl/f) and mean residence time for each subject using a non-
compartmental analysis by using Win Nonlin 5.1 software. 
Statistical comparisons for the pharmacokinetic study among, 
gliclazide, itopride, itopride alone and in combination groups and 
plasma concentration–response study among concentrations and time 
were carried out with student’s paired T-Test a value of P<0.05 was 
considered to be statistically significant. Data were reported as 
mean±SEM linear regressions were used to determine the relationship 
between total plasma concentrations and pharmacokinetic 
parameters. The mean concentration versus time profile of gliclazide 
and itopride in rat plasma is shown in fig. 1, 2, 3 and 4. 
RESULTS AND DISCUSSION 
In the present study, Gliclazide is completely absorbed after oral 
administration with peak plasma concentration of 11.54±2.14µg/ml 
after 2 h of dosing on day 1. In combination with Gliclazide and 
Itopride on day 1, the peak plasma concentration of Gliclazide 
18.33±0.12µg/ml occurred at 2hr after dosing. There was no 
significant increase in peak plasma concentration levels. Similarly 
Itopride is completely absorbed after oral administration with peak 
plasma concentration 3.92±0.03µg/ml occurred at 2hr after dosing 
on day 1 in combination with Gliclazide and Itopride on day 1. 
 
Table 1: Pharmacokinetic parameters of Gliclazide alone and in Combination with Itopride on day 1 
parameters Gliclazide alone Gliclazide combination with Itopride Level of significance(p<0.05) 
Cmax 11.54±2.14 (µg/ml) 18.33±0.12  NS 
tmax 2±0 (h) 2±0  NS 
AUCo-t 137.22±0.74  (µg/ml/h) 176.37±0.52  NS 
AUCo-inf 158.82±2.50  (µg/ml/h) 158.15±1.85  NS 
t½ (h) 11.56±0.28 10.64±0.09  NS 
CL/f (ml/h/kg) 1.18±0.015 2.23±0.01  NS 
V/F (ml/kg) 25.28±0.26 37.56±0.25  NS 
NS: Not Significant 
 
Table 2: Pharmacokinetic parameters of Gliclazide alone and in Combination with Itopride on day 8 
Parameters Gliclazide alone Gliclazide combination with Itopride Level of significance (p<0.05) 
Cmax 25.83±1.11 (µg/ml) 25.41±1.21  NS 
tmax 2±1.26 (h) 2±1.14  NS 
AUCo-t 156.371.24±  (µg/ml/h) 158.8±1.21  NS 
AUCo-inf 178.15±1.45  (µg/ml/h) 196.12±1.31  NS 
t½ (h) 8.78±1.54 9.08±1.41  NS 
CL/f (ml/h/kg) 1.961±0.01 1.92±1.51  NS 
V/F (ml/kg) 26.67±0.52 27.89±1.25  NS 
NS: Not Significant 
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Table 3: Pharmacokinetic parameters of Itopride in diabetic versus healthy male Wistar rats on day 1 
Parameters Itopride in diabetic rats Itopride in healthy rats Level of significance (p<0.05) 
Cmax 3.92±0.07 (µg/ml) 2.72±0.03  NS 
tmax  2±0 (h) 2±0  NS 
AUCo-t 42.49±11.1  (µg/ml/h) 21.9±0.118  NS 
AUCo-inf 59.53±41.7  (µg/ml/h) 27.49±0.808  NS 
t½ (h) 12.22±15.1 12.03±1.11  NS 
CL/f(ml/h/kg) 15.475±12.2 26.71±0.18  NS 
V/F(ml/kg) 459.16±2.1 497.65±3.09  NS 
NS: Not Significant 
 
Table 4: Pharmacokinetic parameters of Itopride in diabetic versus healthy male Wistar rats on day 8 
Parameters Itopride in diabetic rats Itopride in non diabetic rats Level of significance (p<0.05) 
Cmax 4.80±0.04 (µg/ml) 3.65±0.06  NS 
tmax 2±0 (h)  2±0  NS 
AUCo-t 44.11±0.225  (µg/ml/h) 38.22±0.09  NS 
AUCo-inf 61.57±0.43  (µg/ml/h) 67.37±0.336  NS 
t½ (h) 12.49±0.186 18.92±0.009  NS 
CL/f(ml/h/kg) 13.01±0.08 11.88±0.042  NS 
V/F(ml/kg) 255.8±2.192 345.6±0.639  NS 
NS: Not Significant 
 
Table 5: Pharmacokinetic parameters of Itopride alone and in Combination with Gliclazide in diabetic rats on day 1 
Parameters Itopride alone  Itopride with Gliclazide Level of significance(p<0.05) 
Cmax 3.92±0.03 (µg/ml) 4.06±0.03  NS 
tmax 2±0 (h) 2±0  NS 
AUCo-t 33.5±0.20  (µg/ml/h) 41.63±0.20  NS 
AUCo-inf 52.6±0.52  (µg/ml/h) 52.16±0.525  NS 
t½ (h) 15.23±0.27 12.57±0.27  NS 
CL/f(ml/h/kg) 15.43±0.26 19.03±0.26  NS 
V/F(ml/kg) 358.65±4.31 337.66±4.31  NS 
NS: Not Significant 
 
Table 6: Pharmacokinetic parameters of Itopride alone and in Combination with Gliclazide in Diabetic rats on day 8 
parameters Itopride alone  Itopride with Gliclazide Level of significance(p<0.05) 
Cmax 4.80±0.04 (µg/ml) 5.07±0.04  NS 
tmax 2±0 (h) 2±0  NS 
AUCo-t 44±0.225  (µg/ml/h) 51.6±0.25  NS 
AUCo-inf 61.56±0.43  (µg/ml/h) 69.76±0.88  NS 
t½ (h) 12.49±0.18 12.89±0.29  NS 
CL/f(ml/h/kg) 13.01±0.08 13.48±0.03  NS 
V/F(ml/kg) 335.89±2.16 371.1±2.26  NS 
NS: Not Significant 
 
 
Fig. 1: Mean Plasma concentrations (µg/ml) of Gliclazide alone 
and combination with Itopride on day 1 in diabetic male Wistar 
rats (n=6) 
 
Fig. 2: Mean Plasma concentrations (µg/ml) of Gliclazide alone 
and combination with Itopride on day 8 in Diabetic male Wistar 
rats (n=6) 
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Fig. 3: Mean plasma concentrations (µg/ml) of Itopride alone 
and combination with Gliclazide on day 1 in diabetic male 
Wister rats (n=6) 
 
 
Fig. 4: Mean plasma concentrations (µg/ml) of Itopride alone 
and combination with Gliclazide on day 8 in diabetic male 
Wister rats (n=6) 
 
The peak plasma concentration, of Itopride 4.06±0.03µg/ml 
occurred at 2hr after dosing. There was no significant increase in the 
peak plasma concentration levels similarly on day 8 of Gliclazide 
alone and with combination of Gliclazide with Itopride on day 8. 
Peak plasma concentration are 25.83µg/ml and 25.41µg/ml 
respectively similarly Itopride on day 8 and combination with 
Gliclazide concentrations are 4.80± 0.04 µg/ml and 5.07 ± 
0.04µg/ml respectively. There was no significant difference in peak 
plasma concentration on day 8 (P>0.05). A slight differences was 
observed between diabetic and healthy Itopride treated rats on day 
1 and day 8 respectively (P<0.05) on oral administration of Itopride 
alone and with the combination of Gliclazide. With Itopride on day 1 
showed a 2% increase in the AUC 0–24 of Gliclazide compared to 
combinational treatment, similarly. Itopride on day 1 and with 
combination Gliclazide with Itopride on day 1 administration 
resulted in an increase in the AUC 0–24 of Itopride compared with 
combinational treatment. Similarly on day 8 of Gliclazide and 
Itopride in combination treatment were 1.65% and 2.8% increase in 
the AUC0–24 respectively. The mean AUC0–24 
The half life was similar with alone and combination treatment on 
day 1 and day 8. All these changes were not statistically significant 
(P>0.05). The mean clearance (C1/F) was 15.475±0.401 (ml/h/kg) 
and 26.71±0.18 which was reduced to 13.01±0.08 (m1/h/kg) and 
11.58±0.042 (m1/h/kg) upon treatment of Itopride in Diabetic rats 
and Healthy rats on day 1 and day 8 respectively.  
of Itopride in Diabetic 
rats was 33.49± 0.20 µg/ml/h and 44.11 ±0.22µg/ml/h which was 
reduced to 21.9±0.11µg/ml/h and 38.22 ±0.09µg/ml/h Itopride in 
healthy rats on day 1 and day 8 treatment (P<0.05) respectively. 
There was the slight decrease in the clearance (CL/F) rate of 
Gliclazide in combination compared with Gliclazide alone by 2.52% 
and 0.92% on day 1 and day 8 respectively. Similarly there was the 
slight decrease in the clearance (CL/F) of Itopride in combination 
compared with Itopride alone by 4.92% on day 1. On day 8 a slight 
increase in the clearance (CL/F) of Itopride in combination 
compared with Itopride alone by 4.6%.  
Volume of distribution was increased 3.8% and 1.72% in Gliclazide 
alone compared with Gliclazide and Itopride on day 1 and day 8 
respectively. similarly Itopride in diabetic rats versus in healthy rats 
resulted 359.16 and 497.65 on day 1 respectively Itopride alone on 
day 1 and combination with Gliclazide on day 1 administration 
resulted in 1.5% increases of volume distribution (m1/kg) in alone 
Itopride group treated rats similarly on day 8 administration 
resulted in 5.5 increases of volume of distribution in alone Itopride 
treated rats. From the above results there is no significant difference 
of Cmax,tmax, AUC (0–t) and AUC (0-inf) , t½
CONCLUSION 
, Cl/f and V/f on day 1 and day 
8 of Gliclazide and Itopride in both diabetic and healthy rats. 
Potentially the combination use of Gliclazide and Itopride is safe. 
Considering the prevalence of diabetic gastroparesis as well as the 
prescribing pattern of drugs in patients suffering from such 
complications, it is apparent that antidiabetic and gastroparesis 
drugs seem to be potential candidates for concomitant 
administration. Gliclazide and Itopride are prescribed frequently 
together to the diabetic-gastroparesis patients. The present work 
was aimed to confirm the safety of concomitant administration of 
Gliclazide and Itopride in rats without any drug-drug interactions. 
There was no significant change in the serum levels and 
pharmacokinetics parameters of Cmax,tmax, AUC (0–t) and AUC (0-inf)
CONFLICT OF INTERESTS 
, t½, 
Cl/f and V/f on day 1 and day 8 of Gliclazide and Itopride in both 
diabetic and healthy rats. It may be concluded that during 
concomitant administration of Gliclazide and Itopride at therapeutic 
doses, drug–drug interaction does not occur. Therefore, the 
therapeutic dose and the frequency of administration of Gliclazide 
need not be adjusted in Gastroparesis patients with Diabetes.  
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